Company profile
Replimune Group, Inc.
NASDAQ: REPL · Healthcare · Biotechnology
#1 of 1,417 Healthcare companies by revenue
EA Score
——FH 36DQ —GM —SS 67
v0.1 · 35/100 weight · pillars only
↑ market scale, workforce scale · ↓ return on equity, Piotroski F
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$313.9M
Employees
465
as of 2026-09-11
Market cap
$1.1B
as of 2026-09-11
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Net income-$313.9M-$313.9M2026
Operating income-$319.9M-$319.9M2026
Total assets$332.4M$332.4M2026
Liabilities$166.2M$166.2M2026
Equity$166.2M$166.2M2026
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Replimune Group, Inc.’s financial profile?
Replimune Group, Inc. earned -$313.9M in FY2026 net income.
Peers · Healthcare
Odyssey Therapeutics, Inc.——Jade Biosciences, Inc.——Corvus Pharmaceuticals, Inc.——Alto Neuroscience, Inc.——Apnimed, Inc.——Lumexa Imaging Holdings, Inc. Common Stock——Neighbors
Middlesex →Key facts
CEOSushil Patel
SectorHealthcare
IndustryBiotechnology
HeadquartersWoburn, MA
ExchangeNASDAQ: REPL
Employees465
IPO date2018-07-20
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.